Supreme Court Questions Cancer Drug Margin Cap, Seeks Wider Scrutiny of Medicine Prices

A 30% cap faces a broader test

The Supreme Court has questioned why India's proposed 30% trade margin cap should cover only selected cancer medicines when large gaps between procurement prices and patient prices also occur across other drugs and medical devices. The government estimates that the cancer measure could save patients about Rs 2,500 crore annually, but the judges pressed for a wider examination of how prices are set.

A bench of Justices Vikram Nath and Sandeep Mehta heard the case brought by petitioner Kishan Chand Jain against the Ethics and Medical Registration Board, formerly the Medical Council of India, and others. The hearing was reported as taking place on October 12, 2026, with the next hearing scheduled for October 27.

Solicitor General Tushar Mehta said the Union government would announce a list of cancer medicines covered by the cap and update it periodically according to market developments and public health needs. Separate details of the plan indicate that it could cover 110 expensive cancer medicines, including about 35 patented drugs. The list was still being finalised.

The dispute concerns more than the size of a permitted margin. Jain seeks regulation of the initial prices of medicines outside the scheduled category, maximum retail price caps for medical devices and mandatory prescriptions using generic drug names. His argument is that limiting later price increases does not address a medicine that starts with a high price.

The bench challenged the narrow reach of the cancer measure, describing it as addressing only a small part of the pricing problem. Its observations were questions about policy and patient protection, not a final ruling requiring controls across the entire market.

What the cancer cap would actually control

A trade margin is the difference between the price charged at an earlier stage of distribution and the maximum retail price, or MRP, charged to consumers. Under the proposed cancer measure, the relevant starting point is the price to stockist, meaning the price charged to a distributor at the first point of sale.

The proposed limit is 30% of MRP. That is different from allowing a 30% markup on the stockist's purchase price. If the price to stockist is Rs 70, a 30% share of MRP allows a retail price of Rs 100. The Rs 30 difference is 30% of the retail price, but approximately 42.9% of the Rs 70 starting price.

This distinction matters when comparing the proposal with the court's discussion of a 16% cap over the price to retailer. Those percentages use different reference prices and cannot be compared as though they describe the same calculation.

The National Pharmaceutical Pricing Authority, or NPPA, reportedly approved the cancer proposal in principle under Paragraph 19 of the Drugs (Prices Control) Order, 2013, subject to finalising the medicines covered. Reports describe the government as having decided on the cap, while also saying that the list would still be notified. A policy decision therefore should not be mistaken for confirmation that every proposed medicine already has a revised price.

The planned coverage includes branded and generic versions, as well as domestically manufactured and imported versions of the selected medicines. Inexpensive medicines would be excluded. The stated reasoning is that restricting margins on cheaper products could leave too little room to cover distribution and marketing costs.

Where existing price controls stop

The NPPA publishes the Drugs Prices Control Order, the legal framework at the centre of the dispute. Its official index includes a consolidated version amended through May 25, 2023, an amendment dated December 21, 2016 identified as concerning stents, and a further amendment entry dated June 30, 2026. The index alone does not establish the substance of that latest amendment.

Scheduled medicines are covered by ceiling prices under this framework. Their inclusion is tied to the National List of Essential Medicines, and ceiling prices are calculated using market prices of qualifying brands. A ceiling price limits the permitted selling price, rather than simply limiting the distribution margin.

Jain told the court that the framework covers around 1,000 scheduled drugs, while approximately 82% of medicines fall outside the scheduled category. These are the petitioner's figures, not a separately verified count presented by the court.

Non-scheduled medicines are not entirely free of price restrictions. Their MRPs generally cannot increase by more than 10% annually. The petition targets a different issue: the lack of routine upfront price fixation for these medicines. A restriction on annual increases can constrain future changes without making the starting price affordable.

The price examples that drew judicial concern

The bench cited an Indian made cardiac stent with a price to retailer of Rs 5,000 and an MRP of Rs 25,000. On those figures, the MRP is five times the retailer price, with a Rs 20,000 gap. That is a 400% markup on the retailer price, although the difference is not necessarily profit for any single participant in the supply chain.

The judges also linked high margins to concerns about treatment decisions. Their suggestion that a 16% cap could reduce medical interventions by three quarters was a courtroom observation, not an established finding from a clinical study. Mehta responded that cardiac stents were already subject to price caps.

Another example concerned a saline drip line. The bench was quoted as referring to an MRP of Rs 11 and a selling price of Rs 270. As stated, that example describes a sale above the cited MRP, rather than simply a large margin between procurement and retail prices. The product specifications and transaction details were not established in the accounts of the hearing.

Reports differ on the azithromycin example. One gives an MRP of Rs 78.29 and a price to stockist of Rs 2,850. Another gives the same MRP but a stockist price of Rs 28.50. These figures point in opposite directions, so they should not be treated as interchangeable. Using Rs 28.50, the gap is Rs 49.79 and the MRP is about 2.75 times the stockist price.

At an earlier hearing, the court had referred to medicines purchased for approximately Rs 2,700 carrying an MRP of Rs 27,000, a tenfold difference. The bench expressed its concern in blunt terms:

That's broad daylight dacoity with the patients.

The government's defence and the industry's response

Additional Solicitor General Aishwarya Bhati argued that regulation must balance affordability with medicine availability and the operation of the market. She warned that excessive intervention could affect supply and said India already had some of the lowest medicine prices internationally.

Explaining the government's reluctance to regulate every part of the market, Bhati told the bench:

We don't want to control the entire ecosystem of drugs.

The bench responded by asking why the government could not control the full range of medicines. Its central concern was whether existing mechanisms protect patients where the gap between procurement prices and MRPs is substantial. An international comparison of medicine prices does not, by itself, answer whether a particular product carries an excessive margin.

Senior Advocate Kapil Sibal, representing the Indian Pharmaceutical Alliance, maintained that such markups do not occur across most formulations. This puts the breadth of the problem in dispute: the court highlighted striking examples, while the industry contested whether those examples represent the wider market.

The All India Organisation of Chemists and Druggists welcomed the cancer proposal as a way to make margins and MRPs more transparent. It argued that manufacturers determine and print MRPs, and that retailers should not be held responsible for that decision. The organisation also sought a similar exercise for other expensive medicines.

What the earlier cancer exercise achieved

The current proposal builds on a 2019 exercise covering 42 cancer medicines. Reported results included MRP reductions of up to 91% and annual savings of approximately Rs 984 crore. The 91% figure was the largest reported reduction, not an average reduction across every medicine covered.

For the proposed expansion, analysis discussed at an NPPA meeting found average trade markups of approximately 170% on non-scheduled cancer drugs, reaching 700% in some cases. Expected MRP reductions were broadly estimated at 20% to 70%, with annual savings of about Rs 2,500 crore.

The projected savings are roughly 2.5 times the Rs 984 crore reported for the earlier exercise. The proposed coverage of 110 medicines is also about 2.6 times the earlier 42. These comparisons show a larger planned intervention, but they do not prove that savings will grow in direct proportion to the number of medicines included.

The cancer medicine market figures help explain the focus on products outside routine ceiling price control. Annual turnover was put at approximately Rs 12,500 crore, of which scheduled cancer medicines accounted for about Rs 2,250 crore. Scheduled products therefore represented about 18% of turnover, leaving approximately Rs 10,250 crore, or 82%, outside that category.

That 82% turnover share is distinct from Jain's claim that 82% of medicines across the market are non-scheduled. One measures cancer drug sales by value; the other concerns the share of medicines in a regulatory category. The projected Rs 2,500 crore saving equals about 20% of the stated cancer medicine turnover, but remains an estimate rather than a measured result.

Why a smaller margin may still leave treatment unaffordable

Margin controls reduce the gap between a starting price and the final price. They do not necessarily reduce the starting price itself. That limitation is central to concerns about patented medicines, which can lack competing versions that would otherwise put pressure on prices.

K M Gopakumar, co-convenor of the Working Group on Access to Medicines and Treatments, questioned whether the proposal would make many patented cancer drugs affordable. He cited ribociclib as an example of costs rising despite the earlier margin intervention:

This is unlikely to make many of the patented cancer drugs affordable. Despite such capping in 2019, prices of cancer medicines increased. For instance, the monthly cost of ribociclib rose from Rs 58,000 in 2022 to Rs 78,000 in 2025 despite margin capping.

The figures he cited represent an increase of Rs 20,000 a month, or about 34.5%, over that period. They illustrate why a restriction on distribution margins and a restriction on the underlying medicine price are different policy tools.

Research from Tata Memorial Hospital found that only 1.6% of patients who needed targeted treatments or immunotherapy could access them, with cost among the major barriers. Targeted treatments act on particular features of cancer cells, while immunotherapy helps the immune system attack cancer. That finding concerns the patients studied, rather than establishing a national access rate for every cancer treatment.

The practical test is therefore broader than whether printed MRPs decline. It is whether the remaining cost becomes manageable for patients who need repeated treatment. A large percentage reduction can still leave an expensive medicine beyond a household's means.

The starting price remains a critical issue

Concerns about the proposal also extend to how the price to stockist is established. If that starting figure is high, limiting the margin above it may still produce a high MRP. Commercial arrangements involving free units or discounts can also make the recorded price different from the effective cost of the stock purchased.

For that reason, calls for controls based on manufacturing or import costs address a different part of the pricing chain. Such an approach would examine the base from which later prices are calculated, rather than relying only on the gap between the distributor price and the consumer price.

The industry's counterargument is that distribution margins help pay for maintaining supply across the country and do not automatically accrue to manufacturers or retailers as profit. The reported NPPA analysis nevertheless identifies unusually large margins within the non-scheduled cancer segment, giving the government a specific basis for targeted action.

The court proceedings bring these issues together. The government is pursuing a defined cancer intervention, while the petition seeks broader initial price regulation. Mandatory generic prescriptions are another requested measure, but the hearing accounts do not describe a final decision on that demand.

The timeline and what is still undecided

The policy debate spans an earlier cancer pricing exercise, subsequent affordability concerns and the present litigation. The main dates are:

• 2019: A trade margin exercise covered 42 cancer medicines, with reported MRP reductions of up to 91%.
• 2022 to 2025: Gopakumar said ribociclib's monthly cost rose from Rs 58,000 to Rs 78,000 despite margin capping.
• October 12, 2026: The reported Supreme Court hearing questioned why the proposed cancer measure did not extend to other medicines and devices.
• October 27: The matter was listed for a further hearing.

The final cancer medicine list, the notification date and the resulting prices were not settled in the hearing accounts. Periodic reviews were promised, but no fixed review timetable was specified. The Rs 2,500 crore annual saving remains a government projection.

No final direction requiring a uniform 16% margin across medicines and devices was described. Nor was there a decision accepting the petitioner's requests for mandatory generic prescriptions or upfront controls across non-scheduled medicines. The next hearing is the stated opportunity for further consideration of those demands.

The central unresolved distinction is between controlling a distribution margin and controlling the initial price of a medicine. The proposed cancer cap addresses the first. The petition and the court's questions press the government to explain how patients are protected from the second.

Key Points

• The Supreme Court questioned why a proposed 30% trade margin cap should apply only to selected cancer medicines.
• The planned list could cover 110 expensive cancer drugs, including about 35 patented medicines, but was still being finalised.
• The government projects annual patient savings of approximately Rs 2,500 crore.
• A margin of 30% of MRP is different from a 30% markup on the distributor's purchase price.
• The 2019 exercise covered 42 cancer medicines and reportedly saved about Rs 984 crore annually.
• Reports give conflicting stockist prices for the azithromycin example cited in court.
• The petition also seeks initial price controls for non-scheduled medicines, medical device price caps and mandatory generic prescriptions.
• The next hearing was scheduled for October 27; no final order imposing market wide margin controls was described.